What is the best approach to manage aggression in a 79-year-old female patient with dementia, currently taking trazodone and risperidone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The best approach to manage aggression in a 79-year-old female with dementia who is taking trazodone and risperidone involves prioritizing non-pharmacological interventions, as recommended by the most recent guidelines 1.

Non-Pharmacological Interventions

Non-pharmacological strategies should be considered as first-line management for individuals with dementia who are displaying behavior changes, including aggression. This approach is supported by strong recommendations and moderate to low quality of evidence from recent guidelines 1. Key strategies include:

  • Identifying and addressing potential triggers for aggression, such as pain, discomfort, overstimulation, or unmet needs.
  • Creating a calm, structured environment with consistent routines and familiar caregivers.
  • Using validation therapy, distraction techniques, and redirection when agitation begins.
  • Providing structured and tailored activities that are individualized and aligned to current capabilities and take into account previous roles and interests.

Medication Management

For medication management, it is essential to review the current regimen, considering the risks associated with trazodone and risperidone in elderly patients.

  • Risperidone should be used at the lowest effective dose (typically 0.25-0.5mg daily) and for the shortest duration possible due to increased stroke and mortality risks in elderly dementia patients, as highlighted by expert consensus and research evidence 1.
  • Trazodone (25-50mg) may help with sleep and agitation with fewer risks compared to risperidone.
  • If medication adjustments are needed, changes should be made gradually while monitoring for withdrawal effects.
  • Regular reassessment is essential, as dementia symptoms evolve over time.

Prioritizing Patient Safety and Quality of Life

This approach prioritizes patient safety and quality of life by minimizing medication-related risks and emphasizing non-pharmacological interventions. It is crucial to balance addressing immediate behavioral concerns with the potential long-term consequences of medication use in this vulnerable population, as emphasized by recent guidelines and expert consensus 1.

From the FDA Drug Label

WARNINGS AND PRECAUTIONS SECTION 5. 1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis Cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients (mean age 85 years; range 73-97) in trials of risperidone in elderly patients with dementia-related psychosis.

The best approach to manage aggression in a 79-year-old female patient with dementia, currently taking trazodone and risperidone, is not explicitly stated in the provided drug label. However, considering the patient is already taking risperidone, an antipsychotic drug, and given the warnings about increased mortality and cerebrovascular adverse reactions in elderly patients with dementia-related psychosis, caution should be exercised.

  • The patient's current medication regimen and medical history should be carefully evaluated.
  • Given the potential risks associated with risperidone in elderly patients with dementia-related psychosis, alternative treatment options for managing aggression should be considered.
  • The patient should be closely monitored for any adverse reactions or changes in condition. 2

From the Research

Management of Aggression in Dementia

The management of aggression in a 79-year-old female patient with dementia, currently taking trazodone and risperidone, requires a multifaceted approach.

  • Nonpharmacological interventions should be considered as the initial step, using practical and commonsense strategies 3.
  • Caregivers and family should be actively involved in the planning and implementation of behavioral plans 3.
  • It is essential to minimize both medical and nonmedical factors that may be contributing to behaviors 3.

Pharmacological Interventions

When pharmacologic options are required, it is important to choose medications that will target specific behavioral goals, having both practical consideration and the best evidence in mind 3.

  • Antipsychotics, such as risperidone, may be beneficial for agitation associated with psychotic features, but have less demonstrated efficacy for agitation not associated with psychotic features 4.
  • Alternative medications, such as anticonvulsants (e.g., valproate) and serotonergic antidepressants (e.g., trazodone), may be considered, but the evidence is limited and more studies are needed to determine their efficacy 5, 4.

Prevention of Aggression

Preventing aggression in persons with dementia is crucial, and primary care physicians can play a key role by screening for and treating predictive factors, such as depression, pain, and caregiver burden 6.

  • Clinically useful assessment instruments and treatment options are available, and referral sources can be utilized when necessary 6.
  • A formalized process for preventing aggression/agitation, interprofessional collaboration, and support for the nursing team can also be beneficial 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Aggression and Agitation in Dementia.

Continuum (Minneapolis, Minn.), 2018

Research

Treatment of agitation in dementia.

New directions for mental health services, 1997

Research

Sodium valproate in the treatment of behavioral disturbance in dementia.

Journal of geriatric psychiatry and neurology, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.